Related Experiment Video

Updated: May 12, 2026

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Published on: February 24, 2023

Clinical trials in cellular immunotherapy for brain/CNS tumors

Jetan Badhiwala1, William K Decker, Michael E Berens

  • 1Michael G DeGroote School of Medicine, McMaster University, 1280 Main Street W, Hamilton, ON, L8S 4K1, Canada.

Expert Review of Neurotherapeutics
|April 3, 2013
PubMed

Insights

Immunotherapy offers a promising approach for treating high-grade gliomas, a type of malignant brain tumor. This review examines clinical trials of cellular immunotherapy for primary brain tumors, highlighting its potential to improve patient survival.

Area of Science:

  • Neuro-oncology
  • Immunology
  • Clinical Trials

Background:

  • High-grade gliomas are the most frequent primary malignant brain tumors.
  • Conventional treatments like surgery, radiotherapy, and chemotherapy have shown limited success in improving patient survival.
  • There is a critical need for novel therapeutic strategies for these aggressive tumors.

Purpose of the Study:

  • To provide a comprehensive review of clinical trials investigating cellular immunotherapy for primary brain/CNS tumors.
  • To assess the current landscape and potential of immunotherapy in treating high-grade gliomas.
  • To summarize findings from published studies on cellular immunotherapy efficacy and safety.

Main Methods:

  • Systematic review of published clinical trials.
  • Inclusion of studies evaluating cellular immunotherapy in primary brain/CNS tumors.
  • Analysis of trial outcomes, focusing on efficacy and safety data.

Main Results:

  • Immunotherapy leverages the immune system to target tumor cells specifically.
  • This approach aims to minimize damage to healthy brain tissue, offering a potentially safer alternative.
  • Published clinical trials are being evaluated for their effectiveness in treating high-grade gliomas.

Conclusions:

  • Cellular immunotherapy represents a promising frontier in the treatment of high-grade gliomas.
  • Further research and clinical trials are essential to optimize immunotherapy strategies.
  • Immunotherapy holds the potential to significantly improve outcomes for patients with primary brain tumors.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.